Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2016

View Archived Issues

Astellas Pharma advances pipeline in third quarter of fiscal 2015

Roche profiles pipeline progress of fourth quarter 2015

Eisai reflects on accomplishments of third quarter of fiscal 2015

New culture system for seborrheic keratoses allows for the screening of several Akt inhibitors

Taconic launches huNOG-EXL mouse model

Institute of Cancer Research sells portion of sales royalty entitlement to Zytiga

Enyo secures funding to support hepatitis B program

Psyadon's phase II ecopipam study to continue as planned following review

Bharat Biotech announces Zika virus vaccine program

ImmuNext and Janssen start phase I trial of JNJ-61610588 in patients with solid tumors

Pre-IND toxicology studies for anti-tau MAb BIIB-076

LAM Therapeutics closes financing to develop LAM-001 and LAM-002

FDA grants orphan drug designation for AST-OPC1 as treatment of acute spinal cord injury

Chinese scientists patent FXIa inhibitors

Innov17 develops ROR-alpha/ROR-gamma modulators

Pfizer describes TrKA inhibitors

Zhejiang Kanglaite Group reports natural antitumor from Job's tears

Lupin divulges MEK inhibitors

ViaCyte acquires rights to Janssen's BetaLogics assets

Medical device developers Endologix and TriVascular Technologies complete merger

ImmunoGen and Merck & Co. establish new clinical research collaboration

Neumann Diagnostics reports results for CONFIDENCE cervical dysplasia test

NIH grant supports research at Scripps into nuclear receptors

Launch of Unity Biotechnology

Biochemical and PK characterization of BAX-826

Cytori Cell Therapy improves erectile dysfunction after radical prostatectomy

U.K. Medical Research Council launches Zika virus research initiatives

Blincyto increases overall survival compared with standard chemotherapy in B-cell ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...